Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases

Bibliography

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. Egf Receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11
   PubMed Web of Science ®Google Scholar
• Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic Egfr mutations. J Clin Oncol 2008;26:2442-9
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with Alk-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-19
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of Egfr/Kras and presence of Pik3ca/Akt1 mutations. Clin Cancer Res 2012;18:1167-76
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, et al. Eml4-Alk mutations in lung cancer that confer resistance to Alk inhibitors. N Engl J Med 2010;363:1734-9
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in Alk-rearranged lung cancers. Scil Med 2012;4:120ra17
   Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28
   PubMed Web of Science ®Google Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286-98
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92
   PubMed Web of Science ®Google Scholar
• Daskalos A, Nikolaidis G, Xinarianos G, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2009;124:81-7
   PubMed Web of Science ®Google Scholar
• Ehrlich M. DNA Hypomethylation in cancer cells. Epigenomics 2009;1:239-59
   PubMed Web of Science ®Google Scholar
• Wolff EM, Byun HM, Han HF, et al. Hypomethylation of a line-1 promoter activates an alternate transcript of the met oncogene in bladders with cancer. PLoS Genet 2010;6:e1000917
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400
   PubMed Web of Science ®Google Scholar
• Wen B, Wu H, Shinkai Y, et al. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat Genet 2009;41:246-50
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific Cpg Island shores. Nat Genet 2009;41:178-86
   PubMed Web of Science ®Google Scholar
• Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011;43:768-75
   PubMed Web of Science ®Google Scholar
• Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 2006;38:149-53
   PubMed Web of Science ®Google Scholar
• Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-42
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157-8
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-Mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6
   PubMed Web of Science ®Google Scholar
• Gal-Yam EN, Egger G, Iniguez L, et al. Frequent switching of polycomb repressive marks and DNA hypermethylation in the pc3 prostate cancer cell line. Proc Natl Acad Sci USA 2008;105:12979-84
   PubMed Web of Science ®Google Scholar
• Easwaran H, Johnstone SE, Van Neste L, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012;22:837-49
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011;11:726-34
   PubMed Web of Science ®Google Scholar
• Bachman KE, Park BH, Rhee I, et al. Histone Modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95
   PubMed Web of Science ®Google Scholar
• Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004;23:138-49
   PubMed Web of Science ®Google Scholar
• Strunnikova M, Schagdarsurengin U, Kehlen A, et al. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the rassf1a promoter. Mol Cell Biol 2005;25:3923-33
   PubMed Web of Science ®Google Scholar
• Coolen MW, Stirzaker C, Song JZ, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (Lres) reduces transcriptional plasticity. Nat Cell Biol 2010;12:235-46
   Google Scholar
• Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9
   PubMed Web of Science ®Google Scholar
• Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-55
   PubMed Web of Science ®Google Scholar
• Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
   PubMed Web of Science ®Google Scholar
• Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 1999;96:12754-9
   PubMed Web of Science ®Google Scholar
• Licchesi JD, Westra WH, Hooker CM, et al. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 2008;14:2570-8
   PubMed Web of Science ®Google Scholar
• Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008;29:895-904
   PubMed Web of Science ®Google Scholar
• Sterlacci W, Tzankov A, Veits L, et al. A comprehensive analysis of P16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thor Oncol 2011;6:1649-57
   PubMed Web of Science ®Google Scholar
• Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28
   PubMed Web of Science ®Google Scholar
• Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nate Rev Cancer 2006;6:107-16
   PubMed Web of Science ®Google Scholar
• Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with Mrna expression. Genome Res 2012;22:1197-211
   PubMed Web of Science ®Google Scholar
• Shinjo K, Okamoto Y, An B, et al. Integrated analysis of genetic and epigenetic alterations reveals Cpg Island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 2012;33:1277-85
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, et al. Cpg Island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6
   PubMed Web of Science ®Google Scholar
• Lockwood WW, Wilson IM, Coe BP, et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PloS One 2012;7:e37775
   PubMed Web of Science ®Google Scholar
• Jeong S, Liang G, Sharma S, et al. Selective anchoring of DNA methyltransferases 3a and 3b to nucleosomes containing methylated DNA. Mol Cell Biol 2009;29:5366-76
   PubMed Web of Science ®Google Scholar
• Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009;10:805-11
   PubMed Web of Science ®Google Scholar
• Rhee I, Jair KW, Yen RW, et al. Cpg methylation is maintained in human cancer cells lacking Dnmt1. Nature 2000;404:1003-7
   PubMed Web of Science ®Google Scholar
• Rhee I, Bachman KE, Park BH, et al. Dnmt1 and Dnmt3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-6
   PubMed Web of Science ®Google Scholar
• Jair KW, Bachman KE, Suzuki H, et al. De Novo Cpg Island methylation in human cancer cells. Cancer Res 2006;66:682-92
   PubMed Web of Science ®Google Scholar
• Kim H, Kwon YM, Kim JS, et al. Elevated Mrna levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006;107:1042-9
   PubMed Web of Science ®Google Scholar
• Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 5'cpg methylation and poor prognosis in lung cancer. Lung Cancer 2007;55:205-13
   PubMed Web of Science ®Google Scholar
• Lin RK, Wu CY, Chang JW, et al. Dysregulation of P53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010;70:5807-17
   PubMed Web of Science ®Google Scholar
• Tang YA, Lin RK, Tsai YT, et al. Mdm2 Overexpression deregulates the transcriptional control of Rb/E2f leading to DNA methyltransferase 3a overexpression in lung cancer. Clin Cancer Res 2012;18:4325-33
   PubMed Web of Science ®Google Scholar
• Iorio MV, Piovan C, Croce CM. Interplay between micrornas and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010;1799:694-701
   PubMed Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A, et al. Microrna-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3a and 3b. Proc Natl Acad Sci USA 2007;104:15805-10
   PubMed Web of Science ®Google Scholar
• Garzon R, Liu S, Fabbri M, et al. Microrna-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly Dnmt3a and 3b and indirectly Dnmt1. Blood 2009;113:6411-18
   PubMed Web of Science ®Google Scholar
• Agoston AT, Argani P, Yegnasubramanian S, et al. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 2005;280:18302-10
   PubMedGoogle Scholar
• Zhou Q, Agoston AT, Atadja P, et al. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast Cancer cells. Mol Cancer Res 2008;6:873-83
   PubMed Web of Science ®Google Scholar
• Wang J, Hevi S, Kurash JK, et al. The lysine demethylase Lsd1 (Kdm1) is required for maintenance of global DNA methylation. Nat Genet 2009;41:125-9
   PubMed Web of Science ®Google Scholar
• Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 Mrna expression in lung cancer. Lung Cancer 2004;46:171-8
   PubMed Web of Science ®Google Scholar
• Minamiya Y, Ono T, Saito H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011;74:300-4
   PubMed Web of Science ®Google Scholar
• Lv T, Yuan D, Miao X, et al. Over-expression of Lsd1 promotes proliferation, migration and invasion in non-small cell lung cancer. PloS One 2012;7:e35065
   PubMed Web of Science ®Google Scholar
• Wang L, Wang J, Sun S, et al. A novel Dnmt3b subfamily, delta Dnmt3b, is the predominant form of Dnmt3b in non-small cell lung cancer. Int J Oncol 2006;29:201-7
   PubMed Web of Science ®Google Scholar
• Wang J, Walsh G, Liu DD, et al. Expression of delta Dnmt3b variants and its association with promoter methylation of p16 and rassf1a in primary non-small cell lung cancer. Cancer Res 2006;66:8361-6
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim YR, Yoo NJ, et al. Mutational analysis of dnmt3a gene in acute leukemias and common solid cancers. APMIS 2013;121:85-94
   PubMed Web of Science ®Google Scholar
• Gao Q, Steine EJ, Barrasa MI, et al. Deletion of the De Novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci USA 2011;108:18061-6
   PubMed Web of Science ®Google Scholar
• Wu H, Coskun V, Tao J, et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 2010;329:444-8
   PubMed Web of Science ®Google Scholar
• Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012;44:23-31
   Web of Science ®Google Scholar
• Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462:315-22
   PubMed Web of Science ®Google Scholar
• Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010;1799:717-25
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68
   PubMed Web of Science ®Google Scholar
• Bartling B, Hofmann HS, Boettger T, et al. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 2005;49:145-54
   PubMed Web of Science ®Google Scholar
• Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class Ii histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004;112:26-32
   PubMed Web of Science ®Google Scholar
• Schuster-Bockler B, Lehner B. Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 2012;488:504-7
   PubMed Web of Science ®Google Scholar
• Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93
   PubMed Web of Science ®Google Scholar
• Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984;81:6993-7
   PubMed Web of Science ®Google Scholar
• Ferguson AT, Vertino PM, Spitzner JR, et al. Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-Aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 1997;272:32260-6
   PubMed Web of Science ®Google Scholar
• Christman JK. 5-Azacytidine and 5-Aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95
   PubMed Web of Science ®Google Scholar
• Patel K, Dickson J, Din S, et al. Targeting of 5-Aza-2'-deoxycytidine residues by chromatin-associated Dnmt1 induces proteasomal degradation of the free enzyme. Nuc Acids Res 2010;38:4313-24
   PubMed Web of Science ®Google Scholar
• Issa JP, Kantarjian HM. Targeting DNA Methylation. Clin Cancer Res 2009;15:3938-46
   PubMed Web of Science ®Google Scholar
• Juttermann R, Li E, Jaenisch R. Toxicity of 5-Aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-801
   PubMed Web of Science ®Google Scholar
• Oka M, Meacham AM, Hamazaki T, et al. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-Aza-2'-deoxycytidine. Oncogene 2005;24:3091-9
   PubMed Web of Science ®Google Scholar
• Palii SS, Van Emburgh BO, Sankpal UT, et al. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide dna damage that is distinctly influenced by dna methyltransferases 1 and 3b. Mol Cell Biol 2008;28:752-71
   PubMed Web of Science ®Google Scholar
• Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009;23:1019-28
   PubMed Web of Science ®Google Scholar
• Hagemann S, Heil O, Lyko F, et al. Azacytidine and decitabine induce gene-specific and non-random dna demethylation in human cancer cell lines. PloS One 2011;6:e17388
   PubMed Web of Science ®Google Scholar
• Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012;21:430-46
   PubMed Web of Science ®Google Scholar
• Momparler RL, Ayoub J. Potential of 5-Aza-2'-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001;34(Suppl 4):S111-15
   PubMedGoogle Scholar
• Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12:5777-85
   PubMed Web of Science ®Google Scholar
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotech 2010;28:1069-78
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
   PubMed Web of Science ®Google Scholar
• Miyanaga A, Gemma A, Noro R, et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008;7:1923-30
   PubMed Web of Science ®Google Scholar
• Brazelle W, Kreahling JM, Gemmer J, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 2010;5:e14335
   PubMed Web of Science ®Google Scholar
• Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292-300
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, et al. Phase I Trial of the histone deacetylase inhibitor, depsipeptide (Fr901228, Nsc 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of Ms-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-22
   PubMed Web of Science ®Google Scholar
• Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, Ms-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14:4517-25
   PubMed Web of Science ®Google Scholar
• Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin Cancer Res 2008;14:188-98
   PubMed Web of Science ®Google Scholar
• Siu LL, Pili R, Duran I, et al. Phase I Study of Mgcd0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-7
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Inv New Drugs 2008;26:483-8
   PubMed Web of Science ®Google Scholar
• Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (Nsc# 701852) in patients with relapsed non-small cell lung cancer: a wisconsin oncology network phase II study. J Thor Oncol 2009;4:522-6
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Kummar S, Sarantopoulos J, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a national cancer institute organ dysfunction working group study. J Clin Oncol 2010;28:4507-12
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:56-62
   PubMed Web of Science ®Google Scholar
• Witta SE, Jotte RM, Konduri K, et al. randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30:2248-55
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7
   PubMed Web of Science ®Google Scholar
• Boivin AJ, Momparler LF, Hurtubise A, et al. Antineoplastic action of 5-Aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 2002;13:869-74
   PubMed Web of Science ®Google Scholar
• Zhu WG, Lakshmanan RR, Beal MD, et al. DNA Methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61:1327-33
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63:7089-93
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Grimes MJ, Picchi MA, et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011;71:454-62
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764-73
   PubMed Web of Science ®Google Scholar
• Lin J, Gilbert J, Rudek MA, et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 2009;15:6241-9
   PubMed Web of Science ®Google Scholar
• Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008;14:6296-301
   PubMed Web of Science ®Google Scholar
• Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607
   PubMed Web of Science ®Google Scholar
• Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94:1087-92
   PubMed Web of Science ®Google Scholar
• Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2'-Deoxy-5-azacytidine-induced demethylation of the Hmlh1 gene promoter. Cancer Res 2000;60:6039-44
   PubMed Web of Science ®Google Scholar
• Wu J, Hu CP, Gu QH, et al. Trichostatin a sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharm Sinica 2010;31:93-101
   Google Scholar
• Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80
   PubMed Web of Science ®Google Scholar
• Cooper SJ, von Roemeling CA, Kang KH, et al. Reexpression of tumor suppressor, Sfrp1, leads to antitumor synergy of combined Hdac and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther 2012;11:2105-15
   PubMed Web of Science ®Google Scholar
• Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529-38
   PubMed Web of Science ®Google Scholar
• Fu S, Hu W, Iyer R, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011;117:1661-9
   PubMed Web of Science ®Google Scholar
• Matei D, Fang F, Shen C, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012;72:2197-205
   PubMed Web of Science ®Google Scholar